Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
International multicenter open-label trial for acute myeloid leukemia in children and adolescents
2022-500783-35-00Phase 3Suspended
- Sponsor
- German Society for Pediatric Oncology and Hematology
- Start
- Sep 2022
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, open-label trial of cytarabine in acute myeloid leukemia (AML) (3 arms), sponsored by German Society for Pediatric Oncology and Hematology. Primary endpoints: Event Free Survival (EFS) in Group A1-A3, Overall Survival (OS) in Group B and 1 more. Started Sep 2022; status: suspended.
02
Drugs
cytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2022-500783-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500783-35-00.